Novo Nordisk tests own mobile app in phase III trial with insulin hope

An internally-developed mobile app from Novo Nordisk will be part of a phase III trial involving the pharmaceutical company's grand hope insulin icodec. This app will help diabetes patients find their optimal insulin doses based on earlier doses and their blood sugar levels.

Photo: Tidsvilde Stine/Ritzau Scanpix

Read this article for free

Register with your E-mail.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

WS Audiology plans to list subsidiary

Privately-owned hearing aid company WS Audiology, which grew out of the merger between Widex and Sivantos, plans to list, which handles online sales.

Further reading

Related articles

Latest news

See all jobs